Imagine getting a recommended vaccine to stay healthy. Then, months later, you face a heartbreaking early pregnancy loss. You’d never think to connect the two.
But for one specific vaccine, scientists now say the timing might be critically important.
Hepatitis E is a serious liver infection. It is especially dangerous for pregnant women.
A vaccine called HEV239 was created to prevent it. It has been used in some countries.
Earlier research found a worrying signal. Women who got this vaccine during early pregnancy or just before it had more miscarriages. A miscarriage, also called a spontaneous abortion (SAB), is the sudden loss of a pregnancy before 20 weeks.
This was a major red flag. But it left huge questions unanswered.
The Search for a "Why"
The big question was: why? Did the vaccine somehow trigger a reaction in women already prone to miscarriage?
Scientists went back to the data. They looked for clues in the women’s health profiles. They checked if miscarriages happened earlier. They looked for signs of a strong immune reaction after the shot.
They found nothing.
The women who miscarried after the Hepatitis E vaccine were just as healthy as those who miscarried after a different, common vaccine. The pregnancies ended at similar times. The women didn’t report more sore arms or fevers after the shot.
The Surprising Shift
This was a puzzling twist. The increased risk was real. But there was no clear biological story to explain it.
So, researchers asked a different question. Not why, but exactly when?
They stopped looking at broad windows of time. Instead, they counted backwards from a woman’s last menstrual period (LMP)—the best marker for the start of pregnancy. They analyzed the risk for every 30-day block before conception.
What they found was startling.
Pinpointing a Danger Zone
The risk wasn’t spread out evenly. It was concentrated in one very specific period.
Getting the HEV239 vaccine in the 31 to 60 days before pregnancy began was linked to a significantly higher risk. The data suggests the risk was over four times higher compared to getting a standard Hepatitis B vaccine.
Think of it like a hidden timer. If conception happens in that specific month-after-vaccination window, the risk of early pregnancy loss appears to rise.
For vaccinations earlier than 60 days before pregnancy, or during pregnancy itself, this specific spike in risk was not seen in this analysis.
This new analysis looked back at a large trial in China. It involved over 100,000 women. The original trial compared the HEV239 vaccine to a Hepatitis B vaccine. This careful re-examination focused on the roughly 2,000 women from that trial who received a vaccine shortly before or during pregnancy.
The most crucial finding is about timing. The 31-60 day pre-pregnancy window stood out clearly.
The other key finding was the lack of clues. Scientists could not find any difference in the mothers’ health, the stage of pregnancy loss, or their immediate reaction to the shot that explained the risk.
This makes the issue both clearer and more complex.
A Clearer Warning, A Deeper Mystery
We now have a more precise danger window, but zero understanding of the mechanism.
This is the core paradox. It means doctors can give more specific advice. But scientists are left without a target to fix or a process to block.
Researchers state this analysis did not uncover a biological mechanism. The "why" remains hidden. They call for targeted studies, like examining placental tissue or genetic factors, to finally solve this medical mystery. The finding is considered robust, but the pathway from vaccine to pregnancy loss is completely unknown.
If you are a woman of childbearing age, this research is about planning. The HEV239 vaccine is not widely used globally, but it is licensed in some countries.
If you are considering this vaccine, discuss the timing with your doctor. Based on this study, avoiding vaccination in the two months before you plan to try to conceive may be a prudent step.
Do not stop other vaccinations without medical advice. This finding is specific to the HEV239 vaccine. Vaccines for flu, COVID-19, and Tdap are critically important for a healthy pregnancy.
This is a re-analysis of a single, older trial. The number of pregnancies in the key risk window was small. This means the exact size of the risk (the 4.3 times higher figure) could change with more research. The study also could not investigate every possible biological mechanism.
The path forward requires two steps. First, health authorities must use this data to update guidance for this specific vaccine. Second, and more difficult, is the basic science. Researchers need to discover the hidden biological process at work. Until they do, the recommendation will be based on a statistical warning sign, not a scientific understanding. This research journey is far from over.